Page 16 - Sci Communications News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Oncocyte Announces Pricing of $35 Million Public Offering of Common Stock IRVINE, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) — Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced that it has priced the previously announced underwritten public offering of 7,780,000 shares of its common stock, at a public offering price of $4.50 per share. The gross proceeds to the Company from this offering are expected to be approximately $35.0 million, before dedu...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Ziopharm Oncology Announces Election of Robert Postma to its Board of Directors ZIOPHARM Oncology IncFebruary 5, 2021 GMT BOSTON, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP) today announced the election of Robert Postma to its Board of Directors (the “Board”), effective immediately. Mr. Postma is the Founder of WaterMill Asset Management, a sizeable and long-term shareholder of Ziopharm.    James Huang, Chairman of the Board, s...

9 Meters Biopharma, Inc. highlighted at upcoming Truist Securities' CEO Strategic Vision Conference Call Series RALEIGH, NC / ACCESSWIRE / February 3, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, today announced its Executive Management team will participate in the "CEO Strategic Vision" Conference Call Series hosted by hosted by Srikripa Devarakonda, PhD and Robyn Karnauskas, PhD of Truist Securities on Wednesday, February 10, 2021. Please see additional details below: CEO Strategic Vision Conference Call Series Date:...

Our NanoNews Digest Sponsors Home > Press > Arrowhead Pharmaceuticals Files IND for Phase 2b Study of ARO-ANG3 for Treatment of Mixed Dyslipidemia Abstract: Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has submitted an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for a Phase 2b dose-finding clinical study of ARO-ANG3, the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with mixed dyslipidemia. Arrowhead Pharmaceuticals Files IND for Phase 2b Study of ARO-ANG3 for Tr...

Oncocyte Announces $25 Million Registered Offering Offering Led by Current Shareholder and Healthcare Investor, Pura Vida Investments, Substantially Increasing Its Holdings Further Strengthens Balance Sheet to Support Ongoing Commercial and Development Activities across Cancer Care Continuum IRVINE, Calif., Jan. 20, 2021 — Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced that it has entered into definitive agreements with its two largest instit...